Congestive heart failure lifestyle modification: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(2 intermediate revisions by one other user not shown)
Line 7: Line 7:
Lifestyle modification in the management of chronic [[heart failure]] includes salt restriction to 2 to 3 g or less per day, smoking cessation, avoidance of excess alcohol consumption, maintaining weight to within 10% of ideal body weight and daily weight monitoring to allow the early detection of weight gain that would signify fluid retention.
Lifestyle modification in the management of chronic [[heart failure]] includes salt restriction to 2 to 3 g or less per day, smoking cessation, avoidance of excess alcohol consumption, maintaining weight to within 10% of ideal body weight and daily weight monitoring to allow the early detection of weight gain that would signify fluid retention.


==Lifestyle Modifications==
==Lifestyle Modification==
The following lifestyle modifications are recommended in the patient with [[congestive heart failure]]:
The following lifestyle modifications are recommended in the patient with [[congestive heart failure]]:
*Salt restriction to 2 to 3 g or less per day
*Salt restriction to 2 to 3 g or less per day
Line 20: Line 20:
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WS}}
{{WH}}


[[Category:Disease]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]

Latest revision as of 21:06, 29 July 2020

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure lifestyle modification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure lifestyle modification

CDC on Congestive heart failure lifestyle modification

Congestive heart failure lifestyle modification in the news

Blogs on Congestive heart failure lifestyle modification

Directions to Hospitals Treating Congestive heart failure lifestyle modification

Risk calculators and risk factors for Congestive heart failure lifestyle modification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lifestyle modification in the management of chronic heart failure includes salt restriction to 2 to 3 g or less per day, smoking cessation, avoidance of excess alcohol consumption, maintaining weight to within 10% of ideal body weight and daily weight monitoring to allow the early detection of weight gain that would signify fluid retention.

Lifestyle Modification

The following lifestyle modifications are recommended in the patient with congestive heart failure:

  • Salt restriction to 2 to 3 g or less per day
  • Smoking cessation
  • Avoidance of excess alcohol consumption
  • Maintaining weight to within 10% of ideal body weight
  • Daily weight monitoring to allow the early detection of weight gain that would signify fluid retention

Vaccination

The patient should be vaccinated for pneumococcus and influenza.

References

Template:WS Template:WH